Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight-Loss drug tirzepatide could double as psoriasis treatment in new trial

NCT ID NCT06857942

Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study is testing whether adding the weight-loss drug tirzepatide to the standard psoriasis medication ixekizumab helps people with moderate-to-severe plaque psoriasis who are also overweight or obese. About 200 adults will receive tirzepatide injections for up to 12 months. Researchers will measure improvements in skin clearance, quality of life, and weight reduction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide
What this could lead to
If successful, adding tirzepatide to standard psoriasis therapy could help people with psoriasis and excess weight achieve clearer skin and significant weight loss.
What could go wrong
This is an early-phase, open-label study with no placebo group, so results may be less reliable. Tirzepatide can cause gastrointestinal side effects, and not all participants may respond.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2025

Expected to finish

May 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a diagnosis of moderate-to-severe plaque PsO, as defined by a dermatologist or other experienced clinician treated PsO (for example, allergologist, nurse practitioner or physician assistant) * Have body mass index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity) or 27 kg/m² to \<30 kg/m² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular diseases). * Must have initiated treatment with ixekizumab for approximately 3 months (± 1 month) prior to decision to add tirzepatide. * Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline/screening). Exclusion Criteria: * Have currently received ixekizumab for more than 4 months or less than 2 months. * Have had any exposure to tirzepatide or other glucagon-like peptide-1 receptor agonist (GLP-1 RAs), for example, dulaglutide, liraglutide, or semaglutide. * Are currently enrolled in any other clinical study. Other exclusions * Have a known hypersensitivity to tirzepatide or to any of its component. * Have a personal or family history of medullary thyroid cancer. * Have multiple endocrine neoplasia type 2. * Have type I diabetes mellitus. * Have a history of chronic or acute pancreatitis at any time before screening (Visit 1). * Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or nonproliferative diabetic retinopathy that requires acute treatment. * Have a history of ketoacidosis or hyperosmolar state/coma. * Have a history of severe hypoglycemia and hypoglycemia unawareness within the 6 months before screening. * Have a history of severe gastrointestinal complications, including gastroparesis, gastroesophageal reflux disease, dyspepsia, chronic nausea/constipation/vomiting.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Overweight or obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Overweight or obesity Psoriasis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    39 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Austin Institute for Clinical Research

    RECRUITING

    Pflugerville, Texas, 78660, United States

  • Bellaire Dermatology Associates

    RECRUITING

    Bellaire, Texas, 77401, United States

  • Bellevue Dermatology Clinic

    RECRUITING

    Bellevue, Washington, 98104, United States

  • Care Access - Hoboken

    RECRUITING

    Hoboken, New Jersey, 07030, United States

  • Center For Dermatology Clinical Research, Inc.

    RECRUITING

    Fremont, California, 94538, United States

  • Center for Clinical Studies

    RECRUITING

    Houston, Texas, 77004, United States

  • Center for Clinical Studies

    RECRUITING

    Webster, Texas, 77598, United States

  • Columbia Dermatology & Aesthetics

    RECRUITING

    Columbia, South Carolina, 29212, United States

  • David Fivenson, MD, PLC

    RECRUITING

    Ann Arbor, Michigan, 48103, United States

  • Dawes Fretzin Clinical Research Group, LLC

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • DelRicht Research - Thompson's Station

    RECRUITING

    Smyrna, Tennessee, 37167, United States

  • Dermatology Associates of Plymouth Meeting

    RECRUITING

    Plymouth Meeting, Pennsylvania, 19462, United States

  • Dermatology and Skin Cancer Specialists, LLC

    RECRUITING

    Rockville, Maryland, 20850, United States

  • Dermatology of Seattle

    RECRUITING

    Burien, Washington, 98168, United States

  • Encore Medical Research

    RECRUITING

    Hollywood, Florida, 33024, United States

  • Equity Medical

    RECRUITING

    New York, New York, 10023, United States

  • Equity Medical - Bowling Green

    RECRUITING

    Bowling Green, Kentucky, 42104, United States

  • First OC Dermatology Research Inc

    RECRUITING

    Fountain Valley, California, 92708, United States

  • MOORE Clinical Research, Inc. d/b/a TrueBlue Clinical Research

    RECRUITING

    Tampa, Florida, 33607, United States

  • Medical Dermatology Specialists

    RECRUITING

    Phoenix, Arizona, 85006, United States

  • Metro Boston Clinical Partners

    RECRUITING

    Brighton, Massachusetts, 02135, United States

  • Metropolis Dermatology

    RECRUITING

    Los Angeles, California, 90017, United States

  • Modern Research Associates, PLLC

    RECRUITING

    Dallas, Texas, 75231, United States

  • NeoClinical Research

    RECRUITING

    Hialeah, Florida, 33016, United States

  • Northridge Clinical Trials

    RECRUITING

    Northridge, California, 91325, United States

  • Onsite Clinical Solutions - Huntersville

    RECRUITING

    Huntersville, North Carolina, 28078, United States

  • Optima Research - Boardman

    RECRUITING

    Boardman, Ohio, 44512, United States

  • Oregon Dermatology and Research Center

    RECRUITING

    Portland, Oregon, 97210, United States

  • Psoriasis Treatment Center of Central New Jersey

    RECRUITING

    East Windsor, New Jersey, 08520, United States

  • Revival Research Institute, LLC

    RECRUITING

    Cary, North Carolina, 27511, United States

  • Skin Cancer and Dermatology Institute - Reno

    RECRUITING

    Reno, Nevada, 89509, United States

  • Skin Care Research

    RECRUITING

    Hollywood, Florida, 33021, United States

  • Southeast Research Specialists

    RECRUITING

    Douglasville, Georgia, 30135, United States

  • Stracskin

    RECRUITING

    Portsmouth, New Hampshire, 03801, United States

  • Tanner Clinic

    RECRUITING

    Layton, Utah, 84041, United States

  • Texas Dermatology and Laser Specialists

    RECRUITING

    San Antonio, Texas, 78218, United States

  • The Derm Institute of West Michigan

    RECRUITING

    Caledonia, Michigan, 49316, United States

  • The Indiana Clinical Trials Center, PC

    RECRUITING

    Plainfield, Indiana, 46168, United States

  • TruDerm & TruSpa

    RECRUITING

    Wellington, Florida, 33449, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.